Corporate
2025.10.28
Lumosa Share Positive P2 Trial Results
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001 (INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Finance
2025.10.20
Lumosa Announces Details of Upcoming 2025 Institutional Investor Conference
Corporate
2025.10.17
Announcement: Change in Company Spokesperson
Finance
2025.09.19
Lumosa Submits LT3001 Phase 3 Trial Consultation to the US FDA
Finance
2025.04.21
Lumosa Licenses the “T-Cell Enhancement Technology” from UNC
Finance
2025.03.10
Lumosa Ends Phase 2 Trial Early to Facilitate EOP2 Meeting for LT3001 with US FDA